It’d be something of an understatement to say that the medical industry is important to people. It’s virtually impossible for someone to go their entire life without becoming seriously sick or injured at some point. But like a lot of people I never really gave much thought into how these medical developments go from idea to the pharmacy. A recent legal dispute between a medical research company and an investment bank made me appreciate just how complex this process can be.
The research company, Relmada Therapeutics, Inc, is currently in litigation with investment banking firm Laidlaw & Company. At the moment Relmada has had an important victory thanks to the judge’s decision to issue a temporary restraining order and associated injunction against Laidlaw. The decision was made based on Relmada’s accusations that Laidlaw had been issuing intentionally misleading information in an attempt to influence the proceedings. And all of this is due to a conflict over leadership in Relmada. Laidlaw maintains that due to their former financing position they should have control of Relmada. While they, in turn, dispute the claim.
It’d be an understatement to say that it’s a rather convoluted series of events. To better understand the case I decided to check Laidlaw’s own site for some more information on them. My first surprise was simply finding out how old the group is. Laidlaw & Company have actually been around in some form since 1842. I was also surprised to find that they have an extensive international presence. But what I found most noteworthy is the people who run Laidlaw & Company. The senior executives, especially Matthew Eitner and James Ahern, are very well represented within the site.
What impressed me the most about Matthew Eitner and James Ahern is the fact that they seem quite passionate about a lot of things. The information on the site doesn’t simply list their achievements in the business world. It also paints a picture of two people who are very invested in helping people. Their charitable efforts are quite impressive. And in particular I noticed a heavy focus on helping medical efforts. I think this shows that Laidlaw & Company want the best for their investments. The people at the top can be thought of as a company’s conscience. And Laidlaw & Company has people there who obviously care quite a bit about medicine. This leads me to the conclusion that Laidlaw & Company can probably be trusted to do what they feel is the right thing when it comes to any interaction with the medical industry.